Laurus Labs is principally engaged in offering a broad and integrated portfolio of Active Pharmaceuticals Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry.
Financial Results:
Laurus Labs Ltd reported Revenues for Q1FY24 of ₹1,108.00 Crores down from ₹1,495.00 Crore year on year, a fall of 25.89%.
Total Expenses for Q1FY24 of ₹1,097.00 Crores down from ₹1,171.00 Crores year on year, a fall of 6.32%.
Consolidated Net Profit of ₹13.00 Crores down 94.4% from ₹232.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹0.24, down 94.43% from ₹4.31 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.